ID   PC9-OR#1
AC   CVCL_D7FL
RX   PubMed=34145930;
CC   Population: Chinese; Han and Japanese.
CC   Characteristics: The parent cell line transiently expressing the luciferase gene was injected into the leptomeningeal space of SHO mice, after which the mice were treated daily with osimertinib. After continuous treatment with osimertinib for 2 weeks, the mice developed osimertinib resistance and were subsequently treated daily with osimertinib for 2 weeks (PubMed=34145930).
CC   Selected for resistance to: ChEBI; CHEBI_90943; Osimertinib (AZD9291).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 19-12-24; Version: 2
//
RX   PubMed=34145930; DOI=10.1111/cas.15035; PMCID=PMC8409422;
RA   Fukuda, Koji
RA   Otani, Sakiko
RA   Takeuchi, Shinji
RA   Arai, Sachiko
RA   Nanjo, Shigeki
RA   Tanimoto, Azusa
RA   Nishiyama, Akihiro
RA   Naoki, Katsuhiko
RA   Yano, Seiji
RT   "Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a
RT   leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.";
RL   Cancer Sci. 112:3784-3795(2021).
//